BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 33241760)

  • 1. The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada.
    Yong JH; Mainprize JG; Yaffe MJ; Ruan Y; Poirier AE; Coldman A; Nadeau C; Iragorri N; Hilsden RJ; Brenner DR
    J Med Screen; 2021 Jun; 28(2):100-107. PubMed ID: 33241760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study.
    de Jonge L; Worthington J; van Wifferen F; Iragorri N; Peterse EFP; Lew JB; Greuter MJE; Smith HA; Feletto E; Yong JHE; Canfell K; Coupé VMH; Lansdorp-Vogelaar I;
    Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):304-314. PubMed ID: 33548185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.
    van Wifferen F; de Jonge L; Worthington J; Greuter MJE; Lew JB; Nadeau C; van den Puttelaar R; Feletto E; Yong JHE; Lansdorp-Vogelaar I; Canfell K; Coupé VMH;
    J Med Screen; 2022 Jun; 29(2):72-83. PubMed ID: 35100894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-related disruptions to colorectal cancer screening, diagnosis, and treatment could increase cancer Burden in Australia and Canada: A modelling study.
    Worthington J; Sun Z; Fu R; Lew JB; Chan KKW; Li Q; Eskander A; Hui H; McLoughlin K; Caruana M; Peacock S; Yong JHE; Canfell K; Feletto E; Malagón T
    PLoS One; 2024; 19(4):e0296945. PubMed ID: 38557758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammography screening: A major issue in medicine.
    Autier P; Boniol M
    Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis.
    Ward ZJ; Walbaum M; Walbaum B; Guzman MJ; Jimenez de la Jara J; Nervi B; Atun R
    Lancet Oncol; 2021 Oct; 22(10):1427-1437. PubMed ID: 34487693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study.
    Luo Q; O'Connell DL; Yu XQ; Kahn C; Caruana M; Pesola F; Sasieni P; Grogan PB; Aranda S; Cabasag CJ; Soerjomataram I; Steinberg J; Canfell K
    Lancet Public Health; 2022 Jun; 7(6):e537-e548. PubMed ID: 35660215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oncological organized screening programmes in the COVID-19 era: an Italian survey on accrued delays, reboot velocity, and diagnostic delay estimates].
    Mantellini P; Battisti F; Armaroli P; Giubilato P; Ventura L; Zorzi M; Battagello J; Sassoli de Bianchi P; Senore C; Zappa M
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):344-352. PubMed ID: 33412828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer Screening Disparities Before and After the COVID-19 Pandemic.
    Lofters AK; Wu F; Frymire E; Kiran T; Vahabi M; Green ME; Glazier RH
    JAMA Netw Open; 2023 Nov; 6(11):e2343796. PubMed ID: 37983033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, Characteristics, and Outcomes of Interval Breast Cancers Compared With Screening-Detected Breast Cancers.
    Niraula S; Biswanger N; Hu P; Lambert P; Decker K
    JAMA Netw Open; 2020 Sep; 3(9):e2018179. PubMed ID: 32975573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study.
    Maringe C; Spicer J; Morris M; Purushotham A; Nolte E; Sullivan R; Rachet B; Aggarwal A
    Lancet Oncol; 2020 Aug; 21(8):1023-1034. PubMed ID: 32702310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of the interruption of the Dutch breast cancer screening program due to COVID-19: A modelling study.
    Poelhekken K; Greuter MJW; de Munck L; Siesling S; Brokken FB; de Bock GH
    Prev Med; 2023 Jan; 166():107376. PubMed ID: 36493865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of COVID-19 on screening for colorectal, gastric, breast, and cervical cancer in Korea.
    Park H; Seo SH; Park JH; Yoo SH; Keam B; Shin A
    Epidemiol Health; 2022; 44():e2022053. PubMed ID: 35760396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic.
    Chen RC; Haynes K; Du S; Barron J; Katz AJ
    JAMA Oncol; 2021 Jun; 7(6):878-884. PubMed ID: 33914015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of COVID-19 on hospital screening, diagnosis and treatment activities among prostate and colorectal cancer patients in Canada.
    Lee SH; Ojo AT; Halat M; Bleibdrey N; Zhang S; Chalmers R; Zimskind D
    Int J Health Econ Manag; 2023 Sep; 23(3):345-360. PubMed ID: 37005943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.
    Duffy S; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith R; Evans A; Blyuss O; Johns L; Ellis I; Sasieni P; Wale C; Myles J; Moss S
    Health Technol Assess; 2020 Oct; 24(55):1-24. PubMed ID: 33141657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling.
    Alagoz O; Lowry KP; Kurian AW; Mandelblatt JS; Ergun MA; Huang H; Lee SJ; Schechter CB; Tosteson ANA; Miglioretti DL; Trentham-Dietz A; Nyante SJ; Kerlikowske K; Sprague BL; Stout NK;
    J Natl Cancer Inst; 2021 Nov; 113(11):1484-1494. PubMed ID: 34258611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands.
    Dinmohamed AG; Cellamare M; Visser O; de Munck L; Elferink MAG; Westenend PJ; Wesseling J; Broeders MJM; Kuipers EJ; Merkx MAW; Nagtegaal ID; Siesling S
    J Hematol Oncol; 2020 Nov; 13(1):147. PubMed ID: 33148289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cancer screening restart strategies after COVID-19 disruption.
    Kregting LM; Kaljouw S; de Jonge L; Jansen EEL; Peterse EFP; Heijnsdijk EAM; van Ravesteyn NT; Lansdorp-Vogelaar I; de Kok IMCM
    Br J Cancer; 2021 Apr; 124(9):1516-1523. PubMed ID: 33723386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact and Recovery from COVID-19-Related Disruptions in Colorectal Cancer Screening and Care in the US: A Scenario Analysis.
    van den Puttelaar R; Lansdorp-Vogelaar I; Hahn AI; Rutter CM; Levin TR; Zauber AG; Meester RGS
    Cancer Epidemiol Biomarkers Prev; 2023 Jan; 32(1):22-29. PubMed ID: 36215205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.